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Abstract
Objectives: Evaluate whether an intervention applied to general practitioners to prevent clin-
ical inertia had an impact on pain, functionality, and health-related quality of life (HRQoL) of
patients with hip and/or knee osteoarthritis.
Design: This was a cluster-based, multicentre, prospective, randomized, parallel-group study.
Clusters of physicians working were assigned to one of two study groups. Physicians in Group 1
received a training session while those in Group 2 did not.
Setting: Primary Care Health centers representative of the entire Spanish territory.
Participants: 329 general practitioners of primary healthcare centre.
Interventions: The intervention consists of a motivational session to propose a proactive care,
based on current recommendations.
Measurements: Visual analogue scale (VAS); functionality (WOMAC scale) and global perception
of health by SF-12. Effects were measured in two visits six months apart.
Results: A total of 1361 physicians, and 4076 patients participated in the study. No signiﬁcant
differences were observed in the clinical beneﬁt obtained between patients assigned to Group 1
and Group 2. Nevertheless, a signiﬁcant improvement was observed in the combined population
Abbreviations: EULAR, European League Against Rheumatism; HRQoL, Health-related quality of life; MCS, Mental Component Summary;
NSAIDs, Non-steroidal anti-inﬂammatory drugs; PCS, Physical Component Summary; SD, Standard deviation; SF-12v2, Short Form version 2
Health Survey; VAS, Visual Analogue Scale; WOMAC, Western Ontario and McMaster Universities Index.
∗ Autor para correspondencia.
E-mail address: atejedorv@telefonica.net (A. Tejedor Varillas).
♦ The list of members of the ArtroPro Study Group is shown in Appendix 1.
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(Groups 1 + 2) in the VAS (p < 0.001), WOMAC (p < 0.0001) and SF-12v2 (p < 0.001) questionnaires
in Visit 2 compared to Visit 1.
Conclusions: The results indicate that, although this speciﬁc intervention carried out on
physicians did not provide an additional clinical beneﬁt to patients with knee and/or hip
osteoarthritis, an increased awareness of the patient’s disease through the use of function-
ality indexes, as well as the mere fact of being observed, seem to improve patient-reported
pain, functionality and HRQoL.
© 2010 Elsevier España, S.L. All rights reserved.
PALABRAS CLAVE
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Inercia clínica
Estudio ARTRO-PRO: percepción del beneﬁcio clínico y calidad de vida en pacientes
con artrosis de cadera y rodilla
Resumen
Objetivos: Evaluar si una intervención aplicada a médicos de familia para evitar la inercia
clínica tuvo un impacto en el dolor, funcionalidad y calidad de vida relacionada con la salud
(CVRS) de los pacientes con artritis de cadera y/o rodilla.
Disen˜o: Estudio de grupos paralelos de cluster, multicéntrico, prospectivo, aleatorizado. Los
médicos fueron asignados a 2 grupos, el grupo 1 recibieó una sesión de entrenamiento, el grupo
2, no.
Emplazamiento: Centros de salud representativos del territorio espan˜ol.
Participantes: Médicos de familia de 329 centros de salud.
Intervenciones: Consistieron en una sesión motivadora para proponer una atención proactiva,
basada en recomendaciones actualizadas.
Mediciones principales: Escala analógica visual (EVA); funcionalidad (escala WOMAC) y percep-
ción global de salud mediante SF-12 en 2 visitas separadas por 6 meses.
Resultados: Participaron 1.361 médicos y 4.076 pacientes. No se observaron diferencias signi-
ﬁcativas en el beneﬁcio clínico obtenido entre los pacientes asignados al grupo 1 y grupo 2.
Sin embargo, se observó una mejora signiﬁcativa en la población total (grupos 1 + 2) en la EVA
(p < 0,001), WOMAC (p < 0,0001) y el SF-12V2 (p < 0,001) en la visita 2 en comparación con la
visita 1.
Conclusiones: Esta intervención sobre médicos de familia no proporcionó un beneﬁcio clínico
adicional a los pacientes. Se observó en ambos grupos una mayor conciencia de la enfermedad
del paciente por el uso novedoso de índices de funcionalidad y CVRS, que parece mejorar el
dolor percibido, la funcionalidad y la calidad de vida relacionada con la salud.
© 2010 Elsevier España, S.L. Todos los derechos reservados.
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characteristics of osteoarthritis patients attending primaryntroduction
steoarthritis is the most common type of arthritis in
estern populations, and is a major cause of chronic
usculoskeletal pain and mobility disability in elderly
opulations worldwide.1 The prevalence of osteoarthritis
aries depending upon the diagnostic method used (clinical
r radiological), the joint(s) studied, and the characteristics
f the study population; nonetheless, it is considered one
f the ten most disabling diseases in developed countries,
ffecting 10% of men and 18% of women over the age of 60.2
s with other chronic conditions, treatment of osteoarthritis
s complex and involves a combination of pharmacolog-
cal and non-pharmacological measures for its optimal
anagement.3,4
Failure to implement recommendations contained in the
vailable guidelines of any chronic disease is one of sev-
ral factors contributing to clinical inertia. Clinical inertia
s a leading cause of potentially preventable adverse events.
ccording to Phillips et al.5 factors that could contribute to
linical inertia include the overestimation of the quality of
he care delivered by the physician or the underestimation
c
i
ff the number of patients who need an intensiﬁcation of
harmacotherapy. Additionally, other factors that could con-
ribute are that some physicians lack the appropriate knowl-
dge, tools and clinic facilities to deliver adequate care to
atients with chronic diseases.5 As has been demonstrated
n several randomised clinical trials and cohort studies, the
eleterious consequences of clinical inertia for the patient
an be signiﬁcant, especially in certain chronic diseases
uch as diabetes mellitus or arterial hypertension.6--8 Unfor-
unately, information on the impact of clinical inertia on
ther diseases with low mortality but high morbidity, such
s osteoarthritis, is limited or non-existent.
We carried out a cluster-based, multicentre, prospec-
ive, randomised, parallel-group study to evaluate whether
atients with hip and/or knee osteoarthritis would beneﬁt
rom a speciﬁc type of intervention received by their general
ractitioners, which was designed to reduce clinical iner-
ia. Secondary objectives were to learn about the clinicalare clinics, and to identify those factors related to clinical
nertia that, when modiﬁed, may result in clinical beneﬁt
or the patient.
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Materials and methods
Study design
A multicentre, prospective, randomised, parallel-group
study of physician clusters (general practitioners) was per-
formed to compare the effectiveness of two different
healthcare approaches. The study protocol was approved
by the Ethics Committee of the Hospital Universitario 12
de Octubre (Madrid, Spain) and by the Scientiﬁc Commit-
tee of the Spanish Family and Community Medicine Society
(SemFYC).
Study populations
General practitioners (GP) working in the same primary
healthcare centre for a period of at least six months
after the start of the study were selected to partici-
pate in the study. Physicians involved in other studies
related to healthcare improvement in osteoarthritis or
similar were excluded. GP included in the study enrolled
patients who attended their clinics with a diagnosis of hip
and/or knee osteoarthritis according to the criteria of the
American College of Rheumatology.9 Patients who had a
prosthetic treatment of osteoarthritis, a prosthetic implan-
tation planned within the next six months, osteoarthritis
involving exclusively other joints besides the hip or knee,
concomitant diagnosis of other rheumatic disorders, and/or
inability to participate in the study were excluded.
With an anticipated effectiveness of 50% in group 2 and
an estimated clinically relevant difference of at least 10%,
a type I error of 5% and a study power of 90%, the estimated
sample size for this study was 350 primary care centres with
5 general practitioners per site (1,750 GP). Assuming that
10% of physicians would probably drop out, the ﬁnal sample
size estimated for this study was 1,925 GP from the 350
primary care centres.
Study procedures
Clusters of physicians working at the same healthcare cen-
tre for more than six months were randomly assigned with a
ratio 1:3 to one of two study groups. Group 1 (proactive
intervention group) physicians received a speciﬁc scien-
tiﬁc training session on the current management guidelines
of osteoarthritis disease to avoid clinical inertia. Group 2
(control group) physicians did not receive any speciﬁc inter-
vention and, hence, delivered usual healthcare to patients
with hip and/or knee osteoarthritis.
Each GP included the ﬁrst three patients with hip
and/or knee osteoarthritis who fulﬁlled selection criteria
and agreed to participate in the study. Consequently, a total
of 5,775 patients were expected to be included in the study.
The intervention delivered to Group 1 was a single
clinical session of 45-60minutes, in which a family physi-
cian, who had been previously trained, explained the
assessment methods which would be used during the study:
visual analogue scale (VAS) (range 0-100mm),10 Western
Ontario and McMaster Universities (WOMAC)11 and the Short
Form-12 version 2 (SF-12v2) Health Survey12 questionnaires.
Motivational techniques were used and the latest EULAR
evidence-based recommendations for the management of
i
r
o
s67
steoarthritis disease were delivered.3,4 The session was
ddressed to family physicians with daily clinical practice,
ho are supposed to have enough knowledge level to make
ecisions on the patients; thus, the aim of meeting was
o motivate, break the weight that inertia supposes and
enerate proactive behaviour to lead physicians to search
nd update their knowledge of osteoarthritic disease and
ts treatment.
Additionally, GP from both study groups received a brief
ummary of the study protocol, the case report forms, and
he questionnaires which would be used (VAS, WOMAC and
F-12v2). Scores were estimated for four of the health
oncepts (physical functioning, physical role, emotional
ole and mental health) using two items each, while the
emaining four (pain, general health, vitality and social
unctioning) were represented by a single item. All 12 items
re used to calculate the Physical and Mental Component
ummary scores, which yield a mean of 50 and a stan-
ard deviation (SD) of 10.13 Thus, patients are classiﬁed as
bove or below average. If a patient’s physical health dif-
erence score was negative but close to zero, he or she was
onsidered in ‘average’ health. However, if a patient’s score
as around -20, he or she was considered ‘below average’,
r in poor health.14
Patients selected by GP were scheduled for at least
wo visits with a six months interval. During Visit 1, age,
eight, height, medical history, time elapsed since diagno-
is, presence of concomitant diseases, and pharmacological
reatment(s) received were recorded. In addition, patient’s
lobal health perception, general health status, pain and
unctionality were assessed using the SF-12v2, WOMAC
nd VAS questionnaires. During Visit 2, patients underwent
physical examination, information about current phar-
acological and non-pharmacological treatments and the
resence of additional relevant events was recorded, and
F-12v2, WOMAC and VAS tests were administered.
Participating
patients
n=4,076
Group 1
n=1,208
Visit 1
n=1,208
Visit 2
n=1,007
Visit 1 + Visit 2
n=1,007
Visit 1 + Visit 2
n=2,303
Visit 2
n=2,307
Visit 1
n=2,864
Group 2
n=2,868
eneral scheme of the study: Distribution of patients accord-
ng to study groups and visits. Group 1, General Practioners who
eceived a training session and Group 2 which did not receive
ne. Visit 1, ﬁrst visit to the Family Doactor clinic, and Visit 2
ix months later.
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Table 1 Baseline patient characteristics
Characteristic Group 1 Group 2 P
Age (years) n = 1205 n = 2852
Mean (± SD) 68.7 (±9.67) 68.6 (±9.66) 0.794
Gender, n (%) n = 1205 n = 2848
Male 876 (73) 1986 (70)
Female 329 (27) 862 (30) 0.058
Weight (kg) n = 1206 n = 2855
76.3± 12.42 77.1± 12.79 0.102
Height (m) n = 1204 n = 2854
1.60± 8.28 1.61± 8.43 0.011a
Body mass index (kg/m2) n = 1204 n = 2854
29.71± 4.49 29.73± 4.62 0.693
Disease progression (years) n = 1199 n = 2837
Mean (±SD) 9.0 (±6.92) 9.3 (±6.93) 0.197
Type of osteoarthritis, n (%)b n = 1208 n = 2861
Knee 895 (74) 2029 (71) 0.039a
Hip 501 (41) 1286 (45) 0.041a
Hand 136 (11) 316 (11) 0.843
Spine 274 (23) 648 (23) 0.982
Generalized 101 (8) 234 (8) 0.847
Concomitant diseases n (%)b
Arterial hypertension 707 (73) 1715(76) 0.016a
Diabetes mellitus 222 (33) 568 (37) 0.035a
Hiatal hernia/GE reﬂux 209 (33) 485 (36) 0.365
Dyspepsia/Peptic ulcer 167 (27) 431 (32) 0.029a
Ischaemic cardiomyopathy 80 (14) 203 (17) 0.179
Chronic pulmonary disease 68 (12) 200 (16) 0.019a
Treatments received n (%)c
Non-pharmacological treatments
Weight reduction recommendations 600 (75) 1405 (79) 0.013a
Exercise 658 (77) 1443 (80) 0.208
Electrotherapy 71 (12) 184 (15) 0.099
Hydrotherapy 82 (14) 177 (15) 0.733
Therapeutic massage 136 (23) 309 (25) 0.399
Joint sparing/joint protection 96 (17) 186 (15) 0.452
Pharmacological treatment n (%)
Oral analgesics 965 (93) 2252 (92) 0.458
Oral NSAIDs 743 (79) 1877 (82) 0.108
Opioids 80 (12) 243 (16) 0.021a
Topical analgesics 240 (32) 622 (36) 0.405
Topical NSAIDs 403 (52) 1002 (55) 0.021a
SYSADOA 346 (43) 729 (41) 0.396
Intra-articular treatment 67 (10) 176 (11) 0.282
GE: gastroesophageal reﬂux; NSAIDs: non-steroidal anti-inﬂammatory drugs; SD: standard deviation; SYSADOA: symptomatic slow acting
drugs for osteoarthritis.
a Statistically signiﬁcant.
b ore
S
Q
t
S
dPatients may have more than one type of osteoarthritis, and m
c Patients may be receiving more than one treatment.
tatistical analysisualitative variables were expressed as percentages. Con-
inuous variables were described using mean, median,
D, range, and 95% conﬁdence intervals (CI). Frequency
P
w
c
cthan one disease.
istributions of qualitative variables were compared by
earson X2 or Fisher exact tests. Health centre and physician
ere considered random effects, and perception of patient
hanges was considered as ﬁxed effect. All analyses were
arried out using SAS version 9.1 (SAS Institute, Cary, NC).
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Table 2 Global differences between Group 1 and Group 2 in Visit 2 compared with Visit 1
Instrument Visit 2 -- Visit 1 P
Group 1 (mean± SD) Group 2 (mean± SD)
SF-12
Physical Functioning 1.2 ± 14.3 1.3 ± 13.00 0.956
Role Physical 1.4 ± 11.8 1.7 ± 11.5 0.525
Bodily Pain 4.8 ± 27.6 6.1 ± 26.4 0.205
General Health 1.8 ± 23.6 1.6 ± 21.3 0.801
Vitality -0.9 ± 29.3 1.4 ± 27.6 0.049a
Social Functioning 3.3 ± 28.8 2.0 ± 25.1 0.233
Role Emotional 1.5 ± 12.6 1.3 ± 11.9 0.617
Mental Health 3.8 ± 23.0 3.5 ± 21.7 0.736
Physical Component Summary 0.6 ± 6.4 1.0 ± 5.8 0.169
Mental Component Summary 1.1 ± 8.8 0.9 ± 8.5 0.624
WOMAC
Pain -5.1 ± 16.0 -5.3 ± 16.0 0.736
Stiffness -4.6 ± 20.4 -4.1 ± 21.0 0.585
Physical Function -4.3 ± 15.2 -3.9 ± 15.8 0.518
VAS -10.4 ± 19.5 -9.9 ± 18.7 0.516
SF-12v2: Short Form 12-item version 2 Health Survey; VAS: Visual Analogue Scale; WOMAC: Western Ontario and McMaster Universities
T
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iIndex.
a Statistically signiﬁcant.
Results
Between September and October 2007, a total of 1361 GP
were selected: 403 (30%) were assigned to Group 1 and 958
(70%) to Group 2. No signiﬁcant differences were observed
between groups regarding the number of years practicing,
scientiﬁc and academic activity, age and gender.
A total of 4076 patients with hip and/or knee osteoarthri-
tis were included in the study, 1208 (30%) attended by
GP assigned to Group 1 and 2868 (70%) attended by GP
belonging to Group 2. Overall, 1007 (83%) group 1 patients
and 2303 (80%) group 2 patients attended both study visits.
Discontinuation rate was a slightly higher in the control
group (20% vs 17%).
Baseline characteristics of the study groups are described
in Table 1. There were small signiﬁcant differences regard-
ing the type of osteoarthritis (in Group 1, knee osteoarthritis
was more frequently observed: 74% vs. 71%, P=.039; and hip
osteoarthritis less frequently observed: 41% vs 45%, P=.041).
s
i
o
Table 3 Incidence of relevant events in patients assigned to Gro
Event Group 1
%
Spontaneous medical evaluations 76
Induced medical evaluations 78
Referral to other specialists 30
Additional X-ray requests 25
Treatment modiﬁcations 23
Surgical treatment 3
a Statistically signiﬁcant.here were small differences in some concomitant diseases:
rterial hypertension, diabetes mellitus, hiatal hernia or
astroesophageal reﬂux, and dyspepsia or peptic ulcer. A
arge proportion of patients were being treated with non-
harmacological measures. Most of those who were treated
ith pharmacotherapy took: analgesics (>90%), oral and top-
cal non-steroidal anti-inﬂammatory drugs (NSAIDs) (>70%
nd >50%, respectively), and SYSADOAS (Symptomatic Slow
cting Drugs for Osteoarthritis) (>40%). The only differences
bserved were patients receiving topical NSAIDs (P=.021)
nd opioids (P=.021).
No signiﬁcant differences were observed in any of the
tems evaluated by the SF-12v2, the WOMAC or the VAS
uestionnaires in visits 1 and 2 (Table 2), except the vital-
ty evaluated by SF-12v2 (P=.049). In the comparison of the
ncidence of relevant events occurring during the six-month
tudy period (Table 3), Group 1 showed signiﬁcantly more
nduced medical evaluations (P=.011) and less referrals to
ther specialties.
up 1 and Group 2
Group 2 P
% G1 vs G2
78 0.236
73 0.011a
35 0.005a
28 0.055
22 0.208
4 0.238
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Table 4 Global differences between Visit 2 and Visit 1
Instrument Visit 2 -- Visit 1 (mean± SD) P
SF-12
Physical Functioning 1.2 ± 13.4 <0.001a
Role Physical 1.6 ± 11.6 <0.001a
Bodily Pain 5.7 ± 26.7 <0.001a
General Health 1.6 ± 22.0 <0.001a
Vitality 0.7 ± 28.1 0.168
Social Functioning 2.4 ± 26.3 <0.001a
Role Emotional 1.4 ± 12.1 <0.001a
Mental Health 3.6 ± 22.1 <0.001a
Physical Component Summary 0.8 ± 6.0 <0.001a
Mental Component Summary 1.0 ± 8.6 <0.001a
WOMAC
Pain -5.2 ± 16.0 <0.0001a
Stiffness -4.3 ± 20.5 <0.0001a
Physical Function -4.0 ± 15.6 <0.0001a
VAS -10.0 ± 19.0 <0.001a
SF-12 v: Short Form 12-item version 2 Health Survey; VAS: Visual Analogue Scale; WOMAC: Western Ontario and McMaster Universities
Index.
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Comparing the results of the two visits for the whole
tudy population, signiﬁcant differences were observed in
ost of the items evaluated (Table 4).
iscussion
he results of our study can be grouped into three major
bservations: (1) patients with osteoarthritis have a high
egree of comorbidity and a low health-related quality
f life (HRQoL), as reﬂected by the SF-12v2, WOMAC and
AS scores; (2) patients did not seem to obtain a clinical
eneﬁt from the intervention studied, as there were no
igniﬁcant differences between visit 2 and visit 1; and (3)
atient-reported pain, functionality and HRQoL signiﬁcantly
mproved in the overall study population.
Study patients seem to have a higher degree of impair-
ent and a worse health status in relation to the general
panish population. This was tested by Vilagut et al.,12 who
bserved that the mean SF-12v2 Physical Component Sum-
ary (PCS) and Mental Component Summary (MCS) scores
f a representative sample of the Spanish population were
5.05 (SD: 10.17) and 47.81 (SD: 9.20), respectively, indicat-
ng a somewhat better quality of life than our study group.
One limitation of the study is the discontinuation rate,
round 20%, higher than the 10% used to calculate the sam-
le size, despite the motivation strategy, follow-up, phone
nd e-mail reminders. It was not possible to do a systematic
nalysis of discontinued patients, as many were due to job
hanges of GP, but were similar in number in both groups.
he high prevalence of some diseases, like diabetes melli-
us (33% and 37% in the control and intervention group) are
onsistent with the average age of the sample (68 years) and
he existence of high rates of comorbidity.
As regards the clinical beneﬁt obtained by patients
reated by the GP who had received the speciﬁc
t
f
d
antervention, our ﬁndings call for careful interpretation, and
everal aspects must be taken into consideration. Therefore,
espite the efforts to modify clinical inertia in GP, it is likely
hat these were insufﬁcient, probably, among other reasons,
ecause they focus on a single factor.
The observation that HRQoL perception improved signiﬁ-
antly in overall population from Visit 1 to Visit 2, regardless
f the study group, is important. Since the majority of
atients had one or more concomitant diseases, osteoarthri-
is may have been unimportant until enrolment in this study.
hus, a small increase in GP attention may have represented
signiﬁcant change to the patient in the quality of medical
are received, which in turn, had an effect on the HRQoL.
e are aware that the mere fact of having been included
n a study, which produces a psychological effect of being
bserved, may have generated a positive response in the
hysicians, which in turn affected the quality of healthcare
elivered to patients, irrespective of the group assigned to.
his Hawthorne effect is expected in all types of studies
n which the investigator or subject are aware of their
articipation.15 Therefore, the long-term effects on HRQoL
ill need further evaluation.
The results of this study should be interpreted in the
ight of potential limitations. First, considering the chronic
ature of osteoarthritis, the six months follow-up period
ight not have been long enough. Secondly, as discussed
bove, the type of intervention we designed in order to mod-
fy clinical inertia may have fallen short, or the factors we
ntended to modify were not the most appropriate. Never-
heless, since the actual recruitment was 1361 physicians
nd 4076 patients, we consider that the power of the study
s enough to support the main conclusions. Also, although
he fact that approximately 20% of patient data was lost on
ollow-up when an estimation of 10% was initially planned,
oes not invalidate our results. Moreover, it could be an
dditional factor contributing to clinical inertia due to a
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lack of an adequate follow-up of the disease.16 The search
for factors that might contribute to clinical inertia through
interventions on primary care physicians have been used in
other cluster randomised trials,17,18 yielding positive results
regarding the implementation of interventions carried out
on physicians to reduce clinical inertia.18 Future educational
interventions on practitioners could use the recent Clinical
Practice Guidelines for Osteoarthritis of the Royal College
of Physicians as a reference.19
In conclusion, the results suggest that minor interven-
tions, such as an increased awareness of the patient’s
disease through the use of functionality indexes, as well as
the mere fact of being observed, may be improving patient-
reported pain, functionality and HRQoL. Nevertheless,
because this speciﬁc intervention carried out on physicians
to prevent clinical inertia did not provide an additional
clinical beneﬁt to our sample of patients with knee and/or
hip osteoarthritis, efforts should be made to identify poten-
tially modiﬁable factors that lead to clinical inertia other
than physician-related factors.
Background
• Osteoarthritis (OA) is the most common type of
arthritis in Western populations, and is a major cause
of chronic musculoskeletal pain, mobility disability
and health services use in populations worldwide.
• Clinical inertia, do not initiate or intensify
therapy when clinically indicated is described
in many chronic conditions and it also applies to OA.
Contributions of this study
• Patients with osteoarthritis have a high degree of
comorbidity and a low HRQoL, as reﬂected by the
scores obtained in the SF-12v2, WOMAC and VAS
questionnaires;
• Patients did not seem to obtain a clinical beneﬁt from
the intervention we made on their treating general
practitioners, given that inertia was not modiﬁed.
• Minor, in clinic, interventions, such as an increased
awareness of the patient’s disease through the use
of functionality indexes, as well as the mere fact of
being observed, may improve patient-reported pain,
functionality and HRQoL.
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cQoL). Moreover OA is one of the leading causes of pain
nd disability worldwide. Any synovial joint can develop
steoarthritis but hips, knees, ankles and small hand joints
re the peripheral sites most commonly affected. Risk fac-
ors include age older than 50, injury to a joint, obesity,
ompetitive contact sports, and heredity. The number of
